In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amanda Micklus

Principal Analyst, Datamonitor Healthcare

Connecticut, US
Amanda has been tracking corporate strategy and business development activities in the biopharma and medtech industries for more than 10 years. She is a principal analyst with Informa’s Datamonitor Healthcare where she researches and analyzes trends in corporate strategy and dealmaking, and compiles reports for clients. Amanda also writes trends pieces for Informa’s IN VIVO and START-UP publications, and contributes to Informa’s Strategic Transactions deals database, researching and writing analyses on individual biopharma and medtech transactions. Before joining Informa, Amanda spent five years at Purdue Pharma, working as a market research analyst and information searcher. She has a Bachelor of Science degree in Chemistry-Business from the University of Scranton, and a Master of Science in Library & Information Science from Long Island University.
Advertisement
Set Alert for Articles By Amanda Micklus

Latest From Amanda Micklus

Biopharma Quarterly Dealmaking Statistics, Q2 2018

Biopharma financing for the second quarter totaled $12.4 billion, a 25% decrease from Q1 2018. Meanwhile Q2 merger and acquisition deal value reached $101 billion, three-quarters of which came from Takeda's $79 billion takeover of major European player Shire. Alliances – totaling $13.8 billion (a significant decline from the previous quarter's $30.7 billion) – featured large partnerships in the antibody space, the biotechnology industry sector with the highest dollar volume.

Deals Market Intelligence

Deals In Depth: July 2018

Merck & Co. signed a $1.66 billion deal to license Sutro Biopharma’s immune-modulating cytokine derivatives in oncology and autoimmune disease. Boston Scientific announced two acquisitions, Claret Medical in the embolic protection space, and Cryterion Medical, a cryoablation company. Biopharma and device financing slowed down in July.

Deals Financing

Deals In Depth: June 2018

Sanofi teamed up with Translate Bio in an $850 million mRNA vaccine/infectious disease deal. Novartis spun off the device assets of Alcon through a share buyback program worth $5 billion. Strong showings from FOPOs and IPOs boosted biopharma financing to $5.2 billion.

Deals Financing

Deals In Depth: May 2018

In a $969 million deal, Genentech is investing in Lodo Therapeutics’ soil microbiome research to discover natural products. After several offers, Shire agreed a $79 billion takeover by Takeda, which moves into the top 10 pharma companies. Biopharma financing was slightly down while device financing increased, with a large proportion coming from FOPOs.
BioPharmaceutical Medical Device

Deals In Depth: April 2018

For potentially over $1 billion, Boehringer Ingelheim gained an early-stage anti-cancer immunotherapy from OSE. Novartis again expanded its gene therapy capabilities in the $8.4 billion buy of AveXis. Biopharma and device financing both decreased.
Deals Market Intelligence

Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2018

Device fundraising in the first quarter totaled $7.6 billion, thanks to Siemens Healthineers $5.2 billion IPO, which accounted for more than two-thirds of the total. Q1 M&A activity reached $6.7 billion, a significant rise from Q4's $3.9 billion. Similarly, aggregate first quarter diagnostics financings (at $1.5 billion) and M&As (at $543 million) also experienced substantial increases over the previous quarter.

Deals Market Intelligence
See All
Advertisement
UsernamePublicRestriction

Register